ERBB2 and breast carcinoma: Those with HER2-enriched and TNBC subtypes had 5-year overall survival of 73 and 75%, respectively, and 5-year breast cancer-free interval of 74 and 84%, respectively (Additional file 2: Figure S1 and Additional file 3: Figure S2).